SCHEMBL4408488

SCHEMBL4408488

Cc1noc2nc(-c3ccc(F)cc3)c(-c3ccnc(NC(C)c4ccccc4)n3)cc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 4/20 0.55
CSNK1D P48730 2/20 0.55
PRKD3 O94806 1/20 0.55
MAP4K4 O95819 1/20 0.55
LCK P06239 1/20 0.55
LYN P07948 1/20 0.55
MAPK1 P28482 1/20 0.55
AKT2 P31751 1/20 0.55
FLT4 P35916 1/20 0.55
FLT3 P36888 1/20 0.55
FRK P42685 1/20 0.55
MAPK8 P45983 1/20 0.55
MAPK9 P45984 1/20 0.55
CSNK1A1 P48729 1/20 0.55
GSK3A P49840 1/20 0.55
GSK3B P49841 1/20 0.55
CSNK1G2 P78368 1/20 0.55
MAP4K2 Q12851 1/20 0.55
DYRK1A Q13627 1/20 0.55
ERBB4 Q15303 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4408485 1.00 MAPK13 (0.55) MAPK13CSNK1DPRKD3MAP4K4LCK
SCHEMBL2929971 0.84 MAPK13 (0.52) MAPK13CSNK1DPRKD3MAP4K4LCK
SCHEMBL2929968 0.84 MAPK13 (0.52) MAPK13CSNK1DPRKD3MAP4K4LCK
SCHEMBL4406271 0.84 MAPK13 (0.51) MAPK13CSNK1DPRKD3MAP4K4LCK
SCHEMBL4406273 0.84 MAPK13 (0.51) MAPK13CSNK1DPRKD3MAP4K4LCK
SCHEMBL4415845 0.79 MAPK13 (0.52) MAPK13CSNK1DPRKD3MAP4K4LCK
SCHEMBL4415840 0.79 MAPK13 (0.52) MAPK13CSNK1DPRKD3MAP4K4LCK
SCHEMBL27597808 0.79 MAPK13 (0.59) MAPK13CSNK1DPRKD3MAP4K4LCK
SCHEMBL4408259 0.77 MAP4K4 (0.50) MAPK13CSNK1DPRKD3MAP4K4MAPK1
SCHEMBL4412384 0.75 MAPK14 (0.49) MAPK13CSNK1DPRKD3MAP4K4FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2009-10-22 US claimed
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2008-12-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors MAPK1, MAP4K2, MAP3K1 MAPK13 39/4885CSNK1D 172/4885PRKD3 354/4885
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors MAPK1, MAP4K2, MAP3K1 MAPK13 39/4885CSNK1D 172/4885PRKD3 354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.